Musculoskeletal Biology I, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK; Department of Academic Rheumatology, Aintree University Hospital, Liverpool, UK.
Musculoskeletal Biology I, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.
Best Pract Res Clin Rheumatol. 2019 Jun;33(3):101423. doi: 10.1016/j.berh.2019.06.005. Epub 2019 Jul 17.
Fibromyalgia (FM) is one of the most common conditions that rheumatologists encounter. It is characterised by chronic widespread pain, fatigue, sleep disturbances and impaired cognition. The prevalence of comorbid FM among populations with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are considerably higher than among the general population, with pooled prevalence estimates of 18-24% in RA, 14-16% in axSpA and 18% in PsA. Prevalence estimates should be interpreted with care as the criteria for FM have not been validated for use in patients with inflammatory arthritis. Comorbid FM appears to affect assessment of disease severity in these conditions, particularly patient-reported outcome measures, and may influence response to treatment. There is a need for better identification, classification and management of FM in the context of inflammatory rheumatic diseases.
纤维肌痛（FM）是风湿科医生最常遇到的病症之一。其特征为慢性广泛性疼痛、疲劳、睡眠障碍和认知功能受损。类风湿关节炎（RA）、中轴型脊柱关节炎（axSpA）和银屑病关节炎（PsA）患者中合并纤维肌痛的患病率明显高于普通人群，RA 中合并纤维肌痛的患病率估计为 18-24%，axSpA 中为 14-16%，PsA 中为 18%。由于尚未验证纤维肌痛的标准是否适用于患有炎症性关节炎的患者，因此应谨慎解释患病率估计值。合并纤维肌痛似乎会影响这些疾病严重程度的评估，尤其是患者报告的结局指标，并且可能会影响治疗反应。在炎症性风湿性疾病的背景下，需要更好地识别、分类和管理纤维肌痛。
